issu new model reflect recent disclosur scrub key histor
forecast assumpt base evalu comfort high-
end manag guidanc believ bia upsid remain
top pick increas price target
concurr pre-announc ilmn revenu beat earlier
q/q consum revenu growth data overal y/i sequenc consum revenu
growth detail y/i microarray growth issu updat model
reflect updat reflect manag disclosur result
scrub histor assumpt make relat chang forecast assumpt
manag guid revenu growth expect y/i consist
prior expect updat forecast forecast growth y/i
note follow select import assumpt get us y/i revenu
growth reason bia like upsid parenthes novaseq
placement orders/quart plu work backlog get
project believ doesnt reflect acceler associ core lab
hiseq swap out impact singl lane load solut novaseq
exclud bulk order instrument retir hiseq
hiseq would saw recent check suggest
like right novaseq placement forecast like higher hiseq
 annual consum spend reduct per instrument instrument
class even though check suggest could durabl moder
benchtop sequenc total revenu growth even new nextseq dx
microarray growth even though grew consum genet momentum
seem strong ever slightli aggress seemingli still reason growth
assumpt would support revenu growth expect
revenu growth current model ep consist
high end guidanc rang get assumpt
gross margin expand y/i seem low given consum growth improv
year novaseq margin improv annual estim opex
grow get opex forecast seem like lot opex appli
tax rate commentari earlier month suggest right tax rate
one get bit aggress gross margin cut opex model lower
tax rate factor higher revenu growth rate one see ep approach
mayb ridicul continu page
pleas see page report import disclosur
well posit maintain leadership expand high-end genet
tool research market drive robust growth nipt market increasingli displac
exist diagnost establish reimburs act arm dealer
elimin barrier sequenc becom increasingli use oncolog adjac
market believ factor continu translat robust doubl digit revenu
earn growth justifi premium valuat
nextseq key growth driver
continu evolv favor
novaseq unabl catalyz
nextseq placement continu increas
new instruments/kit surpris
strength nextseq placement
sourc revenu
expand use sequenc increas
becom much favor
concern build oper leverag
slow materi
hiseq bigger expect headwind
leader genet tool segment tool diagnost market
segment compani broad portfolio system consum analysi tool
design simplifi genet analysi address rang genom complex price
point throughput enabl research select best solut scientif
challeng market leader next gener sequenc increasingli focus
reproduct health includ nipt act arm dealer emerg oncolog
share nice run describ
may price even fulli reflect street model said feel
appropri increas price target base updat dcf reflect belief
share trade upsid seemingli aggress ep case
compani report cowen compani
yr cagrcomments/guidancetot pre-announc revenu revenu guidanc y/yproduct inst servic includ nextbio sequenc array servic nipt biggest revenu growth y/i revenu growth guid y/yproduct revenu growth salesproduct sequenc revenu growth total revenu growth microarray revenu growth growth expect lower compani total revenu growth cowen
compani report thomson eikon cowen compani
mm except per share guidancenet pre-announc revenu revenu guidanc y/yreport expect slight improv q/q note base current forecast product mix could gener oper opex higher dollar note opex forecast opex incr increas usual non-oper interest expect normal tax rate tax reform expect drive benefit estim loss attribut nci add earn per ep helix grail dilut pre-annc ep helix tax consensu gross op cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk includ limit greater-than-expect reduct academ
govern research fund competit commerci avail potenti
disrupt technolog price pressur caus competit increas demand
lower-pr instrument run-tim cost neg regulatori dynam
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock thermo fisher scientif secur
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
